EVENTS

 
 

MEDIA

14

October

2021

Solebury Trout Fall Private Company Showcase hosted together with BMO

presentation by Michael Hayden, CEO

10

September

2021

European Huntington's disease Network 2021 Remote Meeting

presentation by Michael Hayden, CEO

17

August

2021

Hope in the Wake of Recent Failures in Huntington’s Disease

BioSpace

22

July

2021

LifeSci Partners Private Summer Symposium 

presentation by Michael Hayden, CEO

12

June

2021

Scientists identify precisely how pridopidine works in models of Huntington’s disease

HD Buzz

4

June

2021

Jefferies Virtual Healthcare Conference 

presentation by Michael Hayden, CEO

13

May

2021

WuXi rare disease webinar on Huntington’s disease

presentation by Michael Hayden, CEO

7

April

2021

European Biotech Investor Days

presentation by Michael Hayden, CEO

1

February

2021

HD Insights podcast, episode 22

Michael Hayden, CEO

PRESS RELEASES

Enjoying%20the%20Woods_edited.jpg

November 24 | 2021

Prilenia to Present at the 4th Annual Evercore ISI HealthCONx Conference 

Rock%252520Balancing_edited_edited_edite

November 17 | 2021

Prilenia Receives Fast Track Designation for Pridopidine for the Treatment of Huntington’s Disease

AEnB2Uq9PhzcsbJeaE4Clbtn-DVQaY4nfoWRuddW

November 3 | 2021

Prilenia Closes Oversubscribed $43 Million in Series B Financing Round 

October 20 | 2021

Prilenia and Huntington Study Group Announce Completion of Patient Enrollment Ahead of Schedule in Global Phase 3 PROOF-HD Huntington’s Disease Clinical Trial 

September 10 | 2021

Prilenia to Present at Upcoming Virtual Healthcare Events 

July 12 | 2021

​FDA Grants Orphan Drug Designation for pridopidine for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

July 8 | 2021

Prilenia’s Phase 3 Huntington’s Disease Clinical Trial Achieves
50% Enrollment

June 29 | 2021

​Prilenia receives positive EMA opinion on Orphan Drug Designation 
for pridopidine in ALS 

May 28 | 2021

Prilenia to Present at Jefferies Virtual Healthcare Conference

May 25 | 2021

New research supports pridopidine’s neuroprotective properties in Huntington’s Disease models

May 13 | 2021

Prilenia Achieves 25% Enrollment in its phase 3 HD trial and appoints

Dr. Goldberg as CSO 

April 1 | 2021

​​Prilenia to Present at Stifel, BMO, Needham and the European Biotech Investor Days 

March 8 | 2021

Prilenia to Present at Upcoming Virtual Healthcare Conferences 

January 28 | 2021

Prilenia Enrolls First Subject in Europe in its PROOF-HD Phase 3 Clinical Trial for Huntington’s Disease

January 8 | 2021

Prilenia Announces First Patient Enrolled for Pridopidine Phase 2/3 Platform Trial for ALS

December 16 | 2020

Additional analyses of Efficacy and Safety of Pridopidine for Huntington’s Disease demonstrate positive effect on functional capacity

October 27 | 2020

Prilenia Enrolls First Patients into its PROOF-HD Phase 3 Clinical Trial for Huntington’s Disease in the United State

September 17 | 2020

Huntington Study Group Announces A Partnership with Prilenia Therapeutics to Conduct A Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease

September 10 | 2021

Henk Schuring joins Prilenia as Chief Regulatory and Commercialization Officer

June 3 | 2020

Prilenia Therapeutics raises $62.5M to fund late stage trials in HD and ALS

June 3 | 2020

Presentation by Dr. Michael Hayden at the Jefferies Virtual Conference 

September 18 | 2019

Prilenia’s Pridopidine chosen to participate in the first ever ALS platform trial by the Sean M. Healey & AMG center for ALS at Mass General